<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5897007</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1006932</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-17-02521</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pearls</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Lymphopenia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Lymphopenia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>T Cell Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>T Cell Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>T Cell Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>T Cell Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>T Cell Receptors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Toll-like Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Toll-like Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Toll-like Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Toll-like Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Filoviruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Interferons</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Disabling of lymphocyte immune response by Ebola virus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Younan</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Iampietro</surname><given-names>Mathieu</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0342-4824</contrib-id><name><surname>Bukreyev</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department Microbiology &#x00026; Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Dutch</surname><given-names>Rebecca Ellis</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Kentucky, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>alexander.bukreyev@utmb.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2018</year></pub-date><volume>14</volume><issue>4</issue><elocation-id>e1006932</elocation-id><permissions><copyright-statement>&#x000a9; 2018 Younan et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Younan et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ppat.1006932.pdf"/><funding-group><funding-statement>This study was supported by the NIH grant U19 AI109945-01 Project 2 Molecular Basis for Ebola Virus Immune Paralysis (AB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="7"/></counts></article-meta></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The lethality of the Ebola virus (EBOV) and its risk for public health came to the forefront during the 2013&#x02013;2016 epidemic in West Africa. By the end of the epidemic, 28,616 suspected, probable, and confirmed cases of EBOV infection, including 11,310 fatalities, had been recorded [<xref rid="ppat.1006932.ref001" ref-type="bibr">1</xref>]. For the first time, EBOV reached urban populations and demonstrated its full potential to spread rapidly and cause havoc before an effective containment response could be initiated. In this regard, EBOV can no longer be characterized as a virus that causes small sporadic outbreaks whose lethality limits the potential for larger epidemics. Furthermore, the continued growth of populations and urbanization within endemic regions may result in increased rates of EBOV outbreaks. Although several advancements have led to a basic understanding of the underlying mechanisms associated with the highly pathogenic nature of Ebola Virus Disease (EVD), a specific treatment for EBOV infection has yet to be approved.</p></sec><sec id="sec002"><title>What is the association of lymphopenia with EVD outcome?</title><p>One of the identified links between survival and fatalities following EBOV infection is T-cell death resulting in their reduction in the peripheral blood. This condition, which is clinically known as lymphopenia, significantly impairs the body&#x02019;s ability to fight infection, as T cells are critical to the development of a virus-specific, adaptive immune response. Lymphopenia and its occurrence in fatalities have been observed in mouse and nonhuman primate models of EVD in addition to humans with EVD [<xref rid="ppat.1006932.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="ppat.1006932.ref006" ref-type="bibr">6</xref>]. Unlike HIV infection, in which CD4<sup>+</sup> T cells are directly infected, both CD4<sup>+</sup> and CD8<sup>+</sup> T cells remain refractory to direct infection by EBOV; however, the absolute number of T lymphocytes in peripheral blood perceptibly drops, particularly in patients who succumb to EVD. Patients who survived EBOV infection are able to maintain T lymphocytes throughout the course of infection [<xref rid="ppat.1006932.ref007" ref-type="bibr">7</xref>]. Below, we summarize the previously established mechanisms contributing to the onset of lymphopenia and highlight recent findings that further demonstrate the multifaceted causes that either directly or indirectly leads to T-cell depletion during EBOV infection.</p></sec><sec id="sec003"><title>What are the indirect mechanisms of lymphopenia associated with EBOV infection?</title><sec id="sec004"><title>&#x0201c;Cytokine storm&#x0201d; and receptor-mediated cell death</title><p>A hallmark of EBOV infection is an overexasperated systemic release of inflammatory mediators collectively known as a &#x0201c;cytokine storm.&#x0201d; This burst in inflammatory mediators, which include the release of pro- and anti-inflammatory cytokines, chemokines, free radicals, and coagulation factors, is associated with continuously perpetuated signaling events [<xref rid="ppat.1006932.ref008" ref-type="bibr">8</xref>]. The inability of the immune system to rein in this feedforward loop results in significant damage to tissue and organs [<xref rid="ppat.1006932.ref009" ref-type="bibr">9</xref>]. Such an environment is toxic to T cells, and prolonged exposure results in bystander-mediated cellular death. In particular, Tumor necrosis factor &#x003b1; (TNF&#x003b1;) has been associated with the induction of both apoptotic and necrotic cell death [<xref rid="ppat.1006932.ref010" ref-type="bibr">10</xref>].</p><p>A significant increase in TNF-related apoptosis-inducing ligand (TRAIL) expression has also been observed in human monocytes and macrophages during infection with EBOV <italic>in vitro</italic> [<xref rid="ppat.1006932.ref011" ref-type="bibr">11</xref>], which can contribute to T-cell apoptosis. Lastly, reactive oxygen species (ROS) levels, which are highly toxic to lymphocytes [<xref rid="ppat.1006932.ref012" ref-type="bibr">12</xref>], were significantly higher in human fatal cases in comparison to patients who survived EVD. A recent study demonstrated that survivors of the EBOV epidemic in West Africa exhibited significantly reduced levels of the overall inflammatory response compared to non-survivors [<xref rid="ppat.1006932.ref013" ref-type="bibr">13</xref>]; hence, the key to improving the outcome following EVD may require timely administration of global immunosuppressive agents. In support of this prediction, our recent study demonstrated that administration of Eritoran, a Toll-Like Receptor 4 (TLR4) antagonist, significantly reduced the global inflammatory response and modified, but did not necessarily reduce the innate and adaptive immune responses, leading to increased survival in murine models of EVD and the disease caused by the closely related Marburg virus [<xref rid="ppat.1006932.ref014" ref-type="bibr">14</xref>]. The role of EBOV-mediated interferon (IFN) antagonism in pathogenesis of EVD is well established [<xref rid="ppat.1006932.ref015" ref-type="bibr">15</xref>]. Depletion studies in nonhuman primates demonstrated the involvement of T cells, B cells, and antibodies in vaccine-mediated protection against EBOV [<xref rid="ppat.1006932.ref016" ref-type="bibr">16</xref>, <xref rid="ppat.1006932.ref017" ref-type="bibr">17</xref>], indirectly indicating their role in the natural protection against EBOV. Therefore, successful treatment of EBOV infections requires suppression of the pro-inflammatory component of the immune response without significantly sacrificing the quality and magnitude of both the innate and adaptive immune responses.</p></sec><sec id="sec005"><title>Aberrant transmission of survival signals</title><p>Recent reports have indicated the EBOV infection results in a substantial immune activation [<xref rid="ppat.1006932.ref013" ref-type="bibr">13</xref>, <xref rid="ppat.1006932.ref018" ref-type="bibr">18</xref>]. Under more &#x0201c;normal&#x0201d; circumstances, such as infection with influenza virus, a significant contraction and depletion of activated cells is typically observed, with only a modest percentage of activated cells transitioning into effector memory T cells [<xref rid="ppat.1006932.ref019" ref-type="bibr">19</xref>]. Although yet to be demonstrated <italic>in vivo</italic>, it is likely that the deficient T-cell response and lymphopenia in EBOV-infected patients or animal models of EVD are caused by a partial depletion of antigen-presenting cells (APCs) and/or deficient signaling events needed to initiate and maintain the transition into memory cells. This hypothesis is supported by previous findings demonstrating that the viral envelope glycoprotein (GP) masks its own epitopes as well as cellular surface proteins such as &#x003b2;1 integrin and MHC-I through steric shielding following GP expression on the plasma membrane of infected APCs [<xref rid="ppat.1006932.ref020" ref-type="bibr">20</xref>] (<xref ref-type="fig" rid="ppat.1006932.g001">Fig 1A</xref>). Furthermore, recent findings have demonstrated that EBOV-infected dendritic cells (DCs) have an impaired ability to activate T cells and exhibit a limited capacity to transmit survival signals to T lymphocytes [<xref rid="ppat.1006932.ref021" ref-type="bibr">21</xref>, <xref rid="ppat.1006932.ref022" ref-type="bibr">22</xref>] (<xref ref-type="fig" rid="ppat.1006932.g001">Fig 1B</xref>). Indeed, mechanistic studies demonstrated that biological effects of IFN-inhibiting domains (IIDs) located in EBOV proteins VP35 and VP24 lead to inhibition of T cell receptor (TCR) signal transduction following contact between EBOV-infected DCs and T cells, as disruption of IIDs by point mutations restored the transduction. Specifically, the VP35 and VP24 IIDs were found to cause deficient maturation of DCs [<xref rid="ppat.1006932.ref023" ref-type="bibr">23</xref>], which, upon contact with T cells, did not induce phosphorylation of TCR complex&#x02013;associated adapter molecules ZAP70, PLC&#x003b3;1, and SLP76, resulting in impaired downstream signaling [<xref rid="ppat.1006932.ref024" ref-type="bibr">24</xref>]. The IIDs were also found to inhibit differentiation and activation of human B cells contacting with EBOV-infected APCs. In particular, the rate of B cell differentiation from na&#x000ef;ve to plasma cells was significantly increased in mixed peripheral blood mononuclear cell (PBMC) cultures infected with EBOV that was carrying mutated VP35 IID as compared to wild-type (WT) EBOV [<xref rid="ppat.1006932.ref024" ref-type="bibr">24</xref>]. Surprisingly, the effect extended beyond T and B lymphocytes as the mutation also had a profound effect on human natural killer (NK) cell activation [<xref rid="ppat.1006932.ref024" ref-type="bibr">24</xref>]. This can possibly be explained by some kind of interaction of NK cells with infected DCs, as antigen-specific memory-NK cells were recently identified in rhesus macaques [<xref rid="ppat.1006932.ref025" ref-type="bibr">25</xref>]. While disabling of VP35 IID leads to EBOV attenuation <italic>in vivo</italic> [<xref rid="ppat.1006932.ref026" ref-type="bibr">26</xref>], the available data do not distinguish between the roles of IFN antagonism from the IID-mediated suppression of cell-mediated response in this attenuation. These <italic>in vitro</italic> findings provide initial evidence demonstrating the role of EBOV IIDs in the deficient cell-mediated response, although further studies are required to demonstrate the relative importance of IID-mediated suppression of cell-mediated response for attenuation <italic>in vivo</italic>.</p><fig id="ppat.1006932.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006932.g001</object-id><label>Fig 1</label><caption><p>(A) Role of Evola virus (EBOV) glycoprotein (GP) steric shielding in impairment of T-cell response. Comparison between a typical viral infection and EBOV infection and the role of EBOV GP overexpression on cell surface membrane. (B) Role of EBOV VP35 interferon-inhibiting domain (IID) in suppression and dysregulation of cell-mediated response. Effects of wild-type (wt) EBOV (left) and the mutated virus with VP35 IID disabled by amino acid substitution R312A on dendritic cells (DCs), natural killer (NK) cells, B cells, and T cells. Summarized from references [<xref rid="ppat.1006932.ref020" ref-type="bibr">20</xref>, <xref rid="ppat.1006932.ref023" ref-type="bibr">23</xref>, <xref rid="ppat.1006932.ref024" ref-type="bibr">24</xref>]. APC, antigen-presenting cells; CD-80, -86, cluster of differentiation; VP35, viral protein 35.</p></caption><graphic xlink:href="ppat.1006932.g001"/></fig></sec></sec><sec id="sec006"><title>Do EBOV virions directly interact with T lymphocytes?</title><p>Although the addition of EBOV to isolated T lymphocytes does not result in a productive infection, EBOV virions have recently been shown to directly bind to and activate CD4<sup>+</sup> T cells [<xref rid="ppat.1006932.ref027" ref-type="bibr">27</xref>, <xref rid="ppat.1006932.ref028" ref-type="bibr">28</xref>]. Binding and activation of CD4<sup>+</sup> T cells were shown to occur through at least two identified interactions: between GP with TLR4 [<xref rid="ppat.1006932.ref027" ref-type="bibr">27</xref>], which is consistent with previous studies showing interaction of envelope proteins of a number of viruses with pattern recognition receptors [<xref rid="ppat.1006932.ref029" ref-type="bibr">29</xref>], and between the viral membrane&#x02013;associated phosphatidylserine (PtdSer) and T-cell immunoglobulin-like protein 1 (Tim-1) [<xref rid="ppat.1006932.ref028" ref-type="bibr">28</xref>] (<xref ref-type="fig" rid="ppat.1006932.g002">Fig 2A and 2B</xref>). In both cases, the direct binding of EBOV virions to CD4<sup>+</sup> T cells was shown to result in a burst in cytokine production and ultimately to lead to increased cell death in <italic>in vitro</italic> experiments. The findings suggest that EBOV induces activation of T cells regardless of antigenic specificity of their receptors, which is consistent with recent findings in EBOV-infected patients [<xref rid="ppat.1006932.ref013" ref-type="bibr">13</xref>].</p><fig id="ppat.1006932.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006932.g002</object-id><label>Fig 2</label><caption><title>Mechanisms of Ebola virus (EBOV) interaction with T cells.</title><p>(A) Role of Toll-Like Receptor 4 (TLR-4) and T-cell immunoglobulin-like protein 1 (Tim-1) in binding of EBOV to T cells. (B) Induction of TLR-4 signaling by EBOV and effects of Eritoran. Summarized from references [<xref rid="ppat.1006932.ref017" ref-type="bibr">17</xref>, <xref rid="ppat.1006932.ref027" ref-type="bibr">27</xref>, <xref rid="ppat.1006932.ref028" ref-type="bibr">28</xref>]. PS, phosphatidylserine; TCR, T cell receptor; GP, glycoprotein; DC, dendritic cell; Myd88, myeloid differentiation primary receptor response 88; IRAK-1, -2, -4, interleukin-1 receptor-associated kinase 2, 3, 4; TRAF-3, -6, TNF Receptor Associated Factor 3, 6; TAB-2, -3, TGF-beta-activated kinase 1/MAP3K7 Binding Protein 2; TAK1, transforming growth factor beta activated kinase 1 (MAP3K7); p38, mitogen-activated protein kinase; IKK&#x003b1;, -&#x003b2;, -&#x003b5;, inhibitor of nuclear factor kappa kinase; NF&#x003ba;B, nuclear factor kappa-light-chain-enhancer of activated B cells; RIP1, receptor-interacting protein 1; TRAM1, translocation associated membrane protein 1; TBK1, TANK binding kinase 1; IRF3, interferon regulatory factor 3; IFN&#x003b1;, -&#x003b2;, interferon &#x003b1;, -&#x003b2;.</p></caption><graphic xlink:href="ppat.1006932.g002"/></fig><p>As a multitude of enveloped viruses have been shown to incorporate PtdSer into their viral membranes as a means of apoptotic mimicry [<xref rid="ppat.1006932.ref030" ref-type="bibr">30</xref>], which serves to enhance infectivity, broaden tropism, and promote immune evasion, it is likely that binding of virion-associated PtdSer to Tim-1 may contribute to the pathogenesis of a broad range of viruses. This prospect is supported by findings showing that targeting PtdSer in guinea pigs infected with Lassa virus protects animals from death [<xref rid="ppat.1006932.ref031" ref-type="bibr">31</xref>]. Similarly, infection of Tim-1-knockout mice with EBOV results in a significant survival not observed in WT control mice [<xref rid="ppat.1006932.ref028" ref-type="bibr">28</xref>]. Further investigation into the mechanism of PtdSer incorporation into budding EBOV virions and the feasibility of targeting PtdSer&#x02013;Tim-1 interactions may result in development of treatments.</p><p>All current EBOV vaccines use GP as the sole antigen, which induces protective immune response. Immunization with the vaccine based on the vesicular stomatitis virus&#x02013;(VSV) based vector during the EBOV epidemic in Guinea in 2015 demonstrated 100% protective efficacy [<xref rid="ppat.1006932.ref032" ref-type="bibr">32</xref>], which is a great success, and a recent study demonstrated an acceptable safety profile of the vaccine [<xref rid="ppat.1006932.ref033" ref-type="bibr">33</xref>]. However, a well-controlled clinical study of the VSV-vectored vaccine in Europe demonstrated adverse effects, including arthritis, vasculitis, and dermatitis, which were not observed in the control group of vaccine recipients that received an empty VSV vector, resulting in halting of the trials involving the doses expected to be minimally sufficient for protection (1 &#x000d7; 10<sup>7</sup> and 5 &#x000d7; 10<sup>7</sup> PFU) [<xref rid="ppat.1006932.ref034" ref-type="bibr">34</xref>]. These effects are likely to be related to pro-inflammatory and immunomodulating effects of GP discussed above in the &#x0201c;Cytokine storm&#x0201d; and receptor-mediated cell death section.</p></sec><sec sec-type="conclusions" id="sec007"><title>Conclusions</title><p>It has become clear that pronounced lymphopenia is intimately linked with fatalities caused by EBOV as well as a broad range of pathogens. Notably, this occurrence is a common characteristic of some of the most lethal human diseases: viral hemorrhagic fevers, infections with highly pathogenic influenza viruses, and bacterial sepsis [<xref rid="ppat.1006932.ref035" ref-type="bibr">35</xref>]. Furthermore, it is likely that several of the mechanisms that lead to lymphopenia during these conditions are also at play during the acute phase of chronic infections, causing transient lymphopenia as a result of bystander-mediated cell death (e.g., acute phase of HIV infection). Hence, continually expanding our knowledge of the mechanisms by which viruses cause lymphopenia in the absence of direct infection of lymphocytes may greatly aid in the development of future broad-acting therapeutics that limit or prevent premature lymphocyte death. Such therapies would putatively increase the chances of mounting an antigen-specific adaptive immune response, which would lead to better patient outcome.</p></sec></body><back><ref-list><title>References</title><ref id="ppat.1006932.ref001"><label>1</label><mixed-citation publication-type="other">CDC. 2014 Ebola Outbreak in West Africa&#x02014;Case Counts 2016. [cited March 21, 2018]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html">http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html</ext-link></mixed-citation></ref><ref id="ppat.1006932.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Geisbert</surname><given-names>TW</given-names></name>, <name><surname>Hensley</surname><given-names>LE</given-names></name>, <name><surname>Gibb</surname><given-names>TR</given-names></name>, <name><surname>Steele</surname><given-names>KE</given-names></name>, <name><surname>Jaax</surname><given-names>NK</given-names></name>, <name><surname>Jahrling</surname><given-names>PB</given-names></name>. <article-title>Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses</article-title>. <source>Lab Invest</source>. <year>2000</year>;<volume>80</volume>(<issue>2</issue>):<fpage>171</fpage>&#x02013;<lpage>86</lpage>. .<?supplied-pmid 10701687?><pub-id pub-id-type="pmid">10701687</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>DS</given-names></name>, <name><surname>Hensley</surname><given-names>LE</given-names></name>, <name><surname>Geisbert</surname><given-names>JB</given-names></name>, <name><surname>Jahrling</surname><given-names>PB</given-names></name>, <name><surname>Geisbert</surname><given-names>TW</given-names></name>. <article-title>Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques</article-title>. <source>Viral Immunol</source>. <year>2004</year>;<volume>17</volume>(<issue>3</issue>):<fpage>390</fpage>&#x02013;<lpage>400</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/vim.2004.17.390">10.1089/vim.2004.17.390</ext-link></comment> .<?supplied-pmid 15357905?><pub-id pub-id-type="pmid">15357905</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Ebihara</surname><given-names>H</given-names></name>, <name><surname>Rockx</surname><given-names>B</given-names></name>, <name><surname>Marzi</surname><given-names>A</given-names></name>, <name><surname>Feldmann</surname><given-names>F</given-names></name>, <name><surname>Haddock</surname><given-names>E</given-names></name>, <name><surname>Brining</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>204</volume> Suppl <issue>3</issue>:<fpage>S991</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jir336">10.1093/infdis/jir336</ext-link></comment> ; PubMed Central PMCID: PMCPMC3189992.<?supplied-pmid 21987781?><pub-id pub-id-type="pmid">21987781</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Fisher-Hoch</surname><given-names>SP</given-names></name>, <name><surname>Platt</surname><given-names>GS</given-names></name>, <name><surname>Lloyd</surname><given-names>G</given-names></name>, <name><surname>Simpson</surname><given-names>DI</given-names></name>, <name><surname>Neild</surname><given-names>GH</given-names></name>, <name><surname>Barrett</surname><given-names>AJ</given-names></name>. <article-title>Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management</article-title>. <source>Lancet</source>. <year>1983</year>;<volume>2</volume>(<issue>8358</issue>):<fpage>1055</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 6138602?><pub-id pub-id-type="pmid">6138602</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Baize</surname><given-names>S</given-names></name>, <name><surname>Leroy</surname><given-names>EM</given-names></name>, <name><surname>Mavoungou</surname><given-names>E</given-names></name>, <name><surname>Fisher-Hoch</surname><given-names>SP</given-names></name>. <article-title>Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?</article-title>
<source>Apoptosis</source>. <year>2000</year>;<volume>5</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 11227491?><pub-id pub-id-type="pmid">11227491</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Baize</surname><given-names>S</given-names></name>, <name><surname>Leroy</surname><given-names>EM</given-names></name>, <name><surname>Georges-Courbot</surname><given-names>MC</given-names></name>, <name><surname>Capron</surname><given-names>M</given-names></name>, <name><surname>Lansoud-Soukate</surname><given-names>J</given-names></name>, <name><surname>Debre</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients</article-title>. <source>Nat Med</source>. <year>1999</year>;<volume>5</volume>(<issue>4</issue>):<fpage>423</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/7422">10.1038/7422</ext-link></comment>
<?supplied-pmid 10202932?><pub-id pub-id-type="pmid">10202932</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Chousterman</surname><given-names>BG</given-names></name>, <name><surname>Swirski</surname><given-names>FK</given-names></name>, <name><surname>Weber</surname><given-names>GF</given-names></name>. <article-title>Cytokine storm and sepsis disease pathogenesis</article-title>. <source>Semin Immunopathol</source>. <year>2017</year>;<volume>39</volume>(<issue>5</issue>):<fpage>517</fpage>&#x02013;<lpage>28</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00281-017-0639-8">10.1007/s00281-017-0639-8</ext-link></comment> .<?supplied-pmid 28555385?><pub-id pub-id-type="pmid">28555385</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Q</given-names></name>, <name><surname>Zhou</surname><given-names>YH</given-names></name>, <name><surname>Yang</surname><given-names>ZQ</given-names></name>. <article-title>The cytokine storm of severe influenza and development of immunomodulatory therapy</article-title>. <source>Cell Mol Immunol</source>. <year>2016</year>;<volume>13</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/cmi.2015.74">10.1038/cmi.2015.74</ext-link></comment> ; PubMed Central PMCID: PMCPMC4711683.<?supplied-pmid 26189369?><pub-id pub-id-type="pmid">26189369</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Wajant</surname><given-names>H</given-names></name>, <name><surname>Pfizenmaier</surname><given-names>K</given-names></name>, <name><surname>Scheurich</surname><given-names>P</given-names></name>. <article-title>Tumor necrosis factor signaling</article-title>. <source>Cell Death Differ</source>. <year>2003</year>;<volume>10</volume>(<issue>1</issue>):<fpage>45</fpage>&#x02013;<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.cdd.4401189">10.1038/sj.cdd.4401189</ext-link></comment> .<?supplied-pmid 12655295?><pub-id pub-id-type="pmid">12655295</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Hensley</surname><given-names>LE</given-names></name>, <name><surname>Young</surname><given-names>HA</given-names></name>, <name><surname>Jahrling</surname><given-names>PB</given-names></name>, <name><surname>Geisbert</surname><given-names>TW</given-names></name>. <article-title>Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily</article-title>. <source>Immunol Lett</source>. <year>2002</year>;<volume>80</volume>(<issue>3</issue>):<fpage>169</fpage>&#x02013;<lpage>79</lpage>. <?supplied-pmid 11803049?><pub-id pub-id-type="pmid">11803049</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Hildeman</surname><given-names>DA</given-names></name>, <name><surname>Mitchell</surname><given-names>T</given-names></name>, <name><surname>Kappler</surname><given-names>J</given-names></name>, <name><surname>Marrack</surname><given-names>P</given-names></name>. <article-title>T cell apoptosis and reactive oxygen species</article-title>. <source>J Clin Invest</source>. <year>2003</year>;<volume>111</volume>(<issue>5</issue>):<fpage>575</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI18007">10.1172/JCI18007</ext-link></comment> ; PubMed Central PMCID: PMCPMC151907.<?supplied-pmid 12618509?><pub-id pub-id-type="pmid">12618509</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ruibal</surname><given-names>P</given-names></name>, <name><surname>Oestereich</surname><given-names>L</given-names></name>, <name><surname>Ludtke</surname><given-names>A</given-names></name>, <name><surname>Becker-Ziaja</surname><given-names>B</given-names></name>, <name><surname>Wozniak</surname><given-names>DM</given-names></name>, <name><surname>Kerber</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Unique human immune signature of Ebola virus disease in Guinea</article-title>. <source>Nature</source>. <year>2016</year>;<volume>533</volume>(<issue>7601</issue>):<fpage>100</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature17949">10.1038/nature17949</ext-link></comment> ; PubMed Central PMCID: PMCPMC4876960.<?supplied-pmid 27147028?><pub-id pub-id-type="pmid">27147028</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Younan</surname><given-names>P</given-names></name>, <name><surname>Ramanathan</surname><given-names>P</given-names></name>, <name><surname>Graber</surname><given-names>J</given-names></name>, <name><surname>Gusovsky</surname><given-names>F</given-names></name>, <name><surname>Bukreyev</surname><given-names>A</given-names></name>. <article-title>The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge</article-title>. <source>MBio</source>. <year>2017</year>;<fpage>8</fpage>(2). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mBio.00226-17">10.1128/mBio.00226-17</ext-link></comment> ; PubMed Central PMCID: PMCPMC5405229.<?supplied-pmid 28442605?><pub-id pub-id-type="pmid">28442605</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Messaoudi</surname><given-names>I</given-names></name>, <name><surname>Amarasinghe</surname><given-names>GK</given-names></name>, <name><surname>Basler</surname><given-names>CF</given-names></name>. <article-title>Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus</article-title>. <source>Nat Rev Microbiol</source>. <year>2015</year>;<volume>13</volume>(<issue>11</issue>):<fpage>663</fpage>&#x02013;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrmicro3524">10.1038/nrmicro3524</ext-link></comment> ; PubMed Central PMCID: PMCPMC5201123.<?supplied-pmid 26439085?><pub-id pub-id-type="pmid">26439085</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Sullivan</surname><given-names>NJ</given-names></name>, <name><surname>Hensley</surname><given-names>L</given-names></name>, <name><surname>Asiedu</surname><given-names>C</given-names></name>, <name><surname>Geisbert</surname><given-names>TW</given-names></name>, <name><surname>Stanley</surname><given-names>D</given-names></name>, <name><surname>Johnson</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>CD8(+) cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates</article-title>. <source>Nature medicine</source>. <year>2011</year> Epub 2011/08/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.2447">10.1038/nm.2447</ext-link></comment> .<?supplied-pmid 21857654?><pub-id pub-id-type="pmid">21857654</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Marzi</surname><given-names>A</given-names></name>, <name><surname>Engelmann</surname><given-names>F</given-names></name>, <name><surname>Feldmann</surname><given-names>F</given-names></name>, <name><surname>Haberthur</surname><given-names>K</given-names></name>, <name><surname>Shupert</surname><given-names>WL</given-names></name>, <name><surname>Brining</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>(<issue>5</issue>):<fpage>1893</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1209591110">10.1073/pnas.1209591110</ext-link></comment> ; PubMed Central PMCID: PMCPMC3562844.<?supplied-pmid 23319647?><pub-id pub-id-type="pmid">23319647</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>McElroy</surname><given-names>AK</given-names></name>, <name><surname>Akondy</surname><given-names>RS</given-names></name>, <name><surname>Davis</surname><given-names>CW</given-names></name>, <name><surname>Ellebedy</surname><given-names>AH</given-names></name>, <name><surname>Mehta</surname><given-names>AK</given-names></name>, <name><surname>Kraft</surname><given-names>CS</given-names></name>, <etal>et al</etal>
<article-title>Human Ebola virus infection results in substantial immune activation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2015</year>;<volume>112</volume>(<issue>15</issue>):<fpage>4719</fpage>&#x02013;<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1502619112">10.1073/pnas.1502619112</ext-link></comment> ; PubMed Central PMCID: PMCPMC4403189.<?supplied-pmid 25775592?><pub-id pub-id-type="pmid">25775592</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>McKinstry</surname><given-names>KK</given-names></name>, <name><surname>Strutt</surname><given-names>TM</given-names></name>, <name><surname>Swain</surname><given-names>SL</given-names></name>. <article-title>The effector to memory transition of CD4 T cells</article-title>. <source>Immunol Res</source>. <year>2008</year>;<volume>40</volume>(<issue>2</issue>):<fpage>114</fpage>&#x02013;<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12026-007-8004-y">10.1007/s12026-007-8004-y</ext-link></comment> .<?supplied-pmid 18213525?><pub-id pub-id-type="pmid">18213525</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Reynard</surname><given-names>O</given-names></name>, <name><surname>Borowiak</surname><given-names>M</given-names></name>, <name><surname>Volchkova</surname><given-names>VA</given-names></name>, <name><surname>Delpeut</surname><given-names>S</given-names></name>, <name><surname>Mateo</surname><given-names>M</given-names></name>, <name><surname>Volchkov</surname><given-names>VE</given-names></name>. <article-title>Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins</article-title>. <source>J Virol</source>. <year>2009</year>;<volume>83</volume>(<issue>18</issue>):<fpage>9596</fpage>&#x02013;<lpage>601</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.00784-09">10.1128/JVI.00784-09</ext-link></comment> ; PubMed Central PMCID: PMCPMC2738224.<?supplied-pmid 19587051?><pub-id pub-id-type="pmid">19587051</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Bosio</surname><given-names>CM</given-names></name>, <name><surname>Aman</surname><given-names>MJ</given-names></name>, <name><surname>Grogan</surname><given-names>C</given-names></name>, <name><surname>Hogan</surname><given-names>R</given-names></name>, <name><surname>Ruthel</surname><given-names>G</given-names></name>, <name><surname>Negley</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation</article-title>. <source>J Infect Dis</source>. <year>2003</year>;<volume>188</volume>(<issue>11</issue>):<fpage>1630</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/379199">10.1086/379199</ext-link></comment> .<?supplied-pmid 14639532?><pub-id pub-id-type="pmid">14639532</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Mahanty</surname><given-names>S</given-names></name>, <name><surname>Hutchinson</surname><given-names>K</given-names></name>, <name><surname>Agarwal</surname><given-names>S</given-names></name>, <name><surname>McRae</surname><given-names>M</given-names></name>, <name><surname>Rollin</surname><given-names>PE</given-names></name>, <name><surname>Pulendran</surname><given-names>B</given-names></name>. <article-title>Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses</article-title>. <source>J Immunol</source>. <year>2003</year>;<volume>170</volume>(<issue>6</issue>):<fpage>2797</fpage>&#x02013;<lpage>801</lpage>. .<?supplied-pmid 12626527?><pub-id pub-id-type="pmid">12626527</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Lubaki</surname><given-names>NM</given-names></name>, <name><surname>Ilinykh</surname><given-names>P</given-names></name>, <name><surname>Pietzsch</surname><given-names>C</given-names></name>, <name><surname>Tigabu</surname><given-names>B</given-names></name>, <name><surname>Freiberg</surname><given-names>AN</given-names></name>, <name><surname>Koup</surname><given-names>RA</given-names></name>, <etal>et al</etal>
<article-title>The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>13</issue>):<fpage>7471</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.03316-12">10.1128/JVI.03316-12</ext-link></comment> ; PubMed Central PMCID: PMCPMC3700277.<?supplied-pmid 23616668?><pub-id pub-id-type="pmid">23616668</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Lubaki</surname><given-names>NM</given-names></name>, <name><surname>Younan</surname><given-names>P</given-names></name>, <name><surname>Santos</surname><given-names>RI</given-names></name>, <name><surname>Meyer</surname><given-names>M</given-names></name>, <name><surname>Iampietro</surname><given-names>M</given-names></name>, <name><surname>Koup</surname><given-names>RA</given-names></name>, <etal>et al</etal>
<article-title>The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses</article-title>. <source>PLoS Pathog</source>. <year>2016</year>;<volume>12</volume>(<issue>12</issue>):<fpage>e1006031</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1006031">10.1371/journal.ppat.1006031</ext-link></comment> ; PubMed Central PMCID: PMCPMC5145241.<?supplied-pmid 27930745?><pub-id pub-id-type="pmid">27930745</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Reeves</surname><given-names>RK</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Jost</surname><given-names>S</given-names></name>, <name><surname>Blass</surname><given-names>E</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Schafer</surname><given-names>JL</given-names></name>, <etal>et al</etal>
<article-title>Antigen-specific NK cell memory in rhesus macaques</article-title>. <source>Nat Immunol</source>. <year>2015</year>;<volume>16</volume>(<issue>9</issue>):<fpage>927</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.3227">10.1038/ni.3227</ext-link></comment> ; PubMed Central PMCID: PMCPMC4545390.<?supplied-pmid 26193080?><pub-id pub-id-type="pmid">26193080</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Prins</surname><given-names>KC</given-names></name>, <name><surname>Delpeut</surname><given-names>S</given-names></name>, <name><surname>Leung</surname><given-names>DW</given-names></name>, <name><surname>Reynard</surname><given-names>O</given-names></name>, <name><surname>Volchkova</surname><given-names>VA</given-names></name>, <name><surname>Reid</surname><given-names>SP</given-names></name>, <etal>et al</etal>
<article-title>Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs</article-title>. <source>Journal of virology</source>. <year>2010</year>;<volume>84</volume>(<issue>6</issue>):<fpage>3004</fpage>&#x02013;<lpage>15</lpage>. Epub 2010/01/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.02459-09">10.1128/JVI.02459-09</ext-link></comment> ; PubMed Central PMCID: PMC2826052.<?supplied-pmid 20071589?><pub-id pub-id-type="pmid">20071589</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Iampietro</surname><given-names>M</given-names></name>, <name><surname>Younan</surname><given-names>P</given-names></name>, <name><surname>Nishida</surname><given-names>A</given-names></name>, <name><surname>Dutta</surname><given-names>M</given-names></name>, <name><surname>Lubaki</surname><given-names>NM</given-names></name>, <name><surname>Santos</surname><given-names>RI</given-names></name>, <etal>et al</etal>
<article-title>Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection</article-title>. <source>PLoS Pathog</source>. <year>2017</year>;<volume>13</volume>(<issue>5</issue>):<fpage>e1006397</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1006397">10.1371/journal.ppat.1006397</ext-link></comment> ; PubMed Central PMCID: PMCPMC5456411.<?supplied-pmid 28542576?><pub-id pub-id-type="pmid">28542576</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Younan</surname><given-names>P</given-names></name>, <name><surname>Iampietro</surname><given-names>M</given-names></name>, <name><surname>Nishida</surname><given-names>A</given-names></name>, <name><surname>Ramanathan</surname><given-names>P</given-names></name>, <name><surname>Santos</surname><given-names>RI</given-names></name>, <name><surname>Dutta</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Ebola Virus Binding to Tim-1 on</article-title>
<source>T Lymphocytes Induces a Cytokine Storm. MBio</source>. <year>2017</year>;<fpage>8</fpage>(5). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mBio.00845-17">10.1128/mBio.00845-17</ext-link></comment> ; PubMed Central PMCID: PMCPMC5615193.<?supplied-pmid 28951472?><pub-id pub-id-type="pmid">28951472</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Xagorari</surname><given-names>A</given-names></name>, <name><surname>Chlichlia</surname><given-names>K</given-names></name>. <article-title>Toll-like receptors and viruses: induction of innate antiviral immune responses</article-title>. <source>Open Microbiol J</source>. <year>2008</year>;<volume>2</volume>:<fpage>49</fpage>&#x02013;<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/1874285800802010049">10.2174/1874285800802010049</ext-link></comment> ; PubMed Central PMCID: PMCPMC2593046.<?supplied-pmid 19088911?><pub-id pub-id-type="pmid">19088911</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Amara</surname><given-names>A</given-names></name>, <name><surname>Mercer</surname><given-names>J</given-names></name>. <article-title>Viral apoptotic mimicry</article-title>. <source>Nat Rev Microbiol</source>. <year>2015</year>;<volume>13</volume>(<issue>8</issue>):<fpage>461</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrmicro3469">10.1038/nrmicro3469</ext-link></comment> .<?supplied-pmid 26052667?><pub-id pub-id-type="pmid">26052667</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Soares</surname><given-names>MM</given-names></name>, <name><surname>King</surname><given-names>SW</given-names></name>, <name><surname>Thorpe</surname><given-names>PE</given-names></name>. <article-title>Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases</article-title>. <source>Nat Med</source>. <year>2008</year>;<volume>14</volume>(<issue>12</issue>):<fpage>1357</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.1885">10.1038/nm.1885</ext-link></comment> ; PubMed Central PMCID: PMCPMC2597367.<?supplied-pmid 19029986?><pub-id pub-id-type="pmid">19029986</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Henao-Restrepo</surname><given-names>AM</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>, <name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Dean</surname><given-names>NE</given-names></name>, <name><surname>Edmunds</surname><given-names>WJ</given-names></name>, <name><surname>Camacho</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>386</volume>(<issue>9996</issue>):<fpage>857</fpage>&#x02013;<lpage>66</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(15)61117-5">10.1016/S0140-6736(15)61117-5</ext-link></comment> .<?supplied-pmid 26248676?><pub-id pub-id-type="pmid">26248676</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Agnandji</surname><given-names>ST</given-names></name>, <name><surname>Fernandes</surname><given-names>JF</given-names></name>, <name><surname>Bache</surname><given-names>EB</given-names></name>, <name><surname>Obiang Mba</surname><given-names>RM</given-names></name>, <name><surname>Brosnahan</surname><given-names>JS</given-names></name>, <name><surname>Kabwende</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: A phase I randomised trial</article-title>. <source>PLoS Med</source>. <year>2017</year>;<volume>14</volume>(<issue>10</issue>):<fpage>e1002402</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1002402">10.1371/journal.pmed.1002402</ext-link></comment> ; PubMed Central PMCID: PMCPMC5630143.<?supplied-pmid 28985239?><pub-id pub-id-type="pmid">28985239</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Huttner</surname><given-names>A</given-names></name>, <name><surname>Dayer</surname><given-names>JA</given-names></name>, <name><surname>Yerly</surname><given-names>S</given-names></name>, <name><surname>Combescure</surname><given-names>C</given-names></name>, <name><surname>Auderset</surname><given-names>F</given-names></name>, <name><surname>Desmeules</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial</article-title>. <source>Lancet Infect Dis</source>. <year>2015</year>;<volume>15</volume>(<issue>10</issue>):<fpage>1156</fpage>&#x02013;<lpage>66</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(15)00154-1">10.1016/S1473-3099(15)00154-1</ext-link></comment> .<?supplied-pmid 26248510?><pub-id pub-id-type="pmid">26248510</pub-id></mixed-citation></ref><ref id="ppat.1006932.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Hellman</surname><given-names>J</given-names></name>. <article-title>Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis</article-title>. <source>PLoS Pathog</source>. <year>2015</year>;<volume>11</volume>(<issue>10</issue>):<fpage>e1005088</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1005088">10.1371/journal.ppat.1005088</ext-link></comment> ; PubMed Central PMCID: PMCPMC4591006.<?supplied-pmid 26425845?><pub-id pub-id-type="pmid">26425845</pub-id></mixed-citation></ref></ref-list></back></article>